A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
Helus Pharma™ (NASDAQ:HELP) (Cboe CA:HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed 86% enrollment, keeping the FDA Breakthrough-designated program on track for a topline data readout in Q4 2026. NEW YORK and TORONTO, June 26, 2026 — USA News Group News […]
From the Lab to the Grid: General Fusion Signs a Framework to Bring Fusion Power to Italy
Days after reporting a key plasma-heating result, General Fusion announced a milestone-based framework agreement with Italian renewable-energy company Renexia to pursue the siting, development, and construction of commercial Magnetized Target Fusion power plants in Italy, as it moves toward going public on Nasdaq under the proposed symbol “GFUZ.“ NEW YORK, June 26, 2026 — Equity Insider News Commentary, There […]